A Bioequivalence Study of Doxorubicin Hydrochloride Liposome Injection

Bioequivalence Clinical Trial

Official title:

A Randomized,Open-label, Single-Dose,Two-Cycle,Crossover Bioequivalence Study of Doxorubicin Hydrochloride Liposome Injection Under Advanced Breast Cancers

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04460820
• Other study ID #: DRBX201901/PRO
• Status: Completed
• Phase: N/A
• Start date: July 4, 2019
• Est. completion date: December 23, 2019

Study information

• Verified date: July 2020
• Source: CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

A Randomized,Open-label, Single-Dose,Two-Cycle,Cross- Bioequivalence Study of Doxorubicin Hydrochloride Liposome Injection Under Advanced Breast Cancers.

Description:

Bioequivalence Study of Doxorubicin Hydrochloride Liposome Injection , 20 mg:10 mL (CSPC OuYi Pharmaceutical Technology Co, Ltd), and Caelyx®, 20 mg:10 mL (Janssen-Cilag International NV), in Advanced Breast Cancers.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 32
• Est. completion date: December 23, 2019
• Est. primary completion date: December 23, 2019
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

• 1.Voluntary agreement to provide written informed consent. 2.Patients with locally advanced or metastatic breast cancer diagnosed by histology or cytology,and who may benefit from monotherapy of Doxorubicin liposomes.

3.Females age 18 to 75 years, inclusive. 4.Body weight =45.0 kg, and BSA<1.80m2. 5.The ECOG performance status is 0 to 2. 6.The expected survival time is more than 3 months. 7.Subjects must have laboratory values within the limits described below: ANC =1.5 x 109/L PLT =100 x 109/L HB =90 g/L PT/INR and APTT =1.5 x ULN Cr =1.5 x ULN Serum total bilirubin =1.5 x ULN(OR =3 X ULN for subjects with liver metastases) AST (SGOT) and ALT (SGPT) =2.5 x ULN (OR =5 X ULN for subjects with liver metastases) 8.The subjects had no pregnancy plan and volunteered to use effective contraception and had no egg donation plan within 6 months after entering the study.

9.The subject will be able to communicate well with the investigator and understand and comply with the requirements of the study.

Exclusion Criteria:

• 1.Significant allergy, hypersensitivity or idiosyncratic reactions to doxorubicin and/or any related compounds.

2.Treatments were terminated due to treatment failure or serious adverse reactions in subjects who had previously used doxorubicin liposomes.

3.Patients with severe cardiovascular, lung, liver, kidney, gastrointestinal, endocrine, immune system, skin, musculoskeletal, neurological or psychiatric conditions that the researchers did not consider appropriate for inclusion.

4.Patients who had undergone major surgery within 3 months before screening, or planned to undergo major surgery during the study period.

5.Having a history of alcoholism, drug abuse or drug abuse. 6.The results of alcohol breath test were more than 0.0mg/100ml or drug abuse screening was positive (Methamphetamine, ketamine, MDMA,Tetrahydrocannabinol).

7.Pregnant or breast-feeding female. 8.Positive result to any of the following:

HIV-1/2, hepatitis B and C; syphilis.

9.Study drug prior to radiation or the use of chemotherapy drugs less than 28 days, or other antineoplastic therapy (e.g., endocrine therapy, Chinese medicine treatment, the local radiotherapy of pain relief, etc.) is less than 14 days, or during the study period need to merge the other anti-tumor drug treatment.

10.Impaired cardiac function: QTc>470ms; LVEF(left ventricular ejection fraction) below 50% or below institutional normal at screening; Congestive heart failure of grade= 2 from NYHA classification, myocardial infarction or uncontrolled angina pectoris occurred within 6 months before enrollment; Have had bypass surgery; 11. Blood donation or massive blood loss within 90 days before screening (> 400ml) .

12.The total cumulative dose of doxorubicin was =300mg/m2 before screening, or previous administration of anthracycline caused severe cardiotoxicity.

13.Eating a specific diet (such as grapefruit) within 48 hours prior to enrollment can affect drug absorption, distribution, metabolism, and excretion.

14.Participating in other clinical trials and accepting clinical trial drugs within 28 days prior to enrollment.

15.Other researchers judged unsuitable for participation.

Related Conditions & MeSH terms

• Bioequivalence

Intervention

Drug:
• Doxorubicin Hydrochloride Liposome Injection
50mg/m2,IV on Day 1 of each cycle

Locations

Country	Name	City	State
China	Fourth Hospital of Hebei Medical University	Shijiazhuang	Hebei

Sponsors (1)

Lead Sponsor	Collaborator
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Cmax	The pharmacokinetics(PK) profile of Doxorubicin Hydrochloride Liposome Injection	up to 15 days post-adminstration
Primary	AUC	The pharmacokinetics(PK) profile of Doxorubicin Hydrochloride Liposome Injection	up to 15 days post-adminstration
Primary	Tmax	The pharmacokinetics(PK) profile of Doxorubicin Hydrochloride Liposome Injection	up to 15 days post-adminstration